Zymeworks Inc. (ZYME)
| Market Cap | 2.04B +46.7% |
| Revenue (ttm) | 37.13M -69.8% |
| Net Income | -149.99M |
| EPS | -2.01 |
| Shares Out | 70.96M |
| PE Ratio | n/a |
| Forward PE | 14.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 584,451 |
| Open | 29.20 |
| Previous Close | 28.90 |
| Day's Range | 28.53 - 29.50 |
| 52-Week Range | 16.00 - 31.34 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 41.50 (+44.55%) |
| Earnings Date | Nov 9, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $41.5, which is an increase of 44.55% from the latest price.
News
Zymeworks Transcript: Investor update
The Roche deal funds ZW209 development while preserving milestone and royalty upside. ZW191 showed activity at both doses in heavily pretreated ovarian cancer, and partner data reported 27-month median OS for the ZIIHERA triplet in first-line advanced GEA.
Zymeworks Press release: Investor update
Zymeworks issued a press release on October 27, 2026, disclosing material business information to investors.
Zymeworks Slides: Investor update
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Zymeworks Proxy statement: Proxy filing
Zymeworks filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Zymeworks Proxy statement: Proxy filing
Zymeworks filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Zymeworks presents new clinical data from Phase 1 study of ZW191
Zymeworks (ZYME) presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRalpha-targeting antibody-drug conjugate, ADC, at the Europ...
Zymeworks presents new clinical data on Phase 1 study of ZW191
Zymeworks (ZYME) presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRalpha-targeting antibody-drug conjugate, ADC, at the Europ...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...
Zymeworks price target raised to $52 from $50 at Jefferies
Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive…
Zymeworks signs collaboration and license agreement with Roche for ZW209
Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercialization of ZW209, a T cell engager targe...
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks Proxy statement: Proxy filing
Zymeworks filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
Zymeworks price target raised to $34 from $32 at Truist
Truist raised the firm’s price target on Zymeworks (ZYME) to $34 from $32 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Zymeworks Slides: Corporate presentation
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Zymeworks reinstated with a Buy at TD Cowen
TD Cowen analyst Yaron Werber reinstated coverage of Zymeworks (ZYME) with a Buy rating and $34 price target after the company closed the Theravance acquisition. The firm views the Theravance…
Zymeworks price target raised to $39 from $38 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $39 from $38 and keeps a Buy rating on the shares. The firm says the close of the Theravance deal…
LifeSci flags Yupelri as a key growth driver after Zymeworks’ Theravance deal
LifeSci Capital notes Zymeworks (ZYME) announced the completion of the Theravance Biopharma (TBPH) acquisition. Yupelri is expected to be immediately accretive to revenue and cash flow, with a mid-tee...
Zymeworks Transcript: M&A announcement
The Theravance acquisition is closed, adding YUPELRI cash flows, an R&D portfolio, and Irish tax attributes. Non-recourse financing supports the deal; base-case returns are mid-teens IRR, excluding several potential upside sources.
Zymeworks Press release: M&A announcement
Zymeworks issued a press release on September 28, 2026, disclosing material business information to investors.
Zymeworks Slides: M&A announcement
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M
With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanced gastroesophageal adenocarcinoma on August 25, 2026...
Zymeworks announces financial impact of Theravance Biopharma acquisition
The acquisition is expected to provide Zymeworks (ZYME) with meaningful and immediate incremental revenue and operating cash flow following closing, including: Mid-teens base-case IRR, supported prima...